European Medicines Agency; Release; 2012 Jun 22.
The EMA concludes that the benefits of Doribax (doripenem) continue to outweigh its risks but recommends updating the prescribing information to allow using a higher dose in certain patients with hospital-acquired pneumonia and to clarify the recommendations and warnings on the use of Doribax in different types of bacterial infection.

Weblink here